Last edition
News about "AviadoBio"
AviadoBio Broadens vMiX Platform Agreement with King's College London
AviadoBio has expanded its exclusive vMiX Precision Gene Silencing Platform agreement with King’s College London to cover all human therapeutic areas. Backed by positive AVB-406 preclinical data, the RNAi-based platform highlights broad potential for targeted gene therapies.
AviadoBio | 17/06/2026 | By News Bureau
AviadoBio Advances AVB-101, Starts New Cohort in Phase 1/2 ASPIRE-FTD Trial
AviadoBio advances AVB-101 gene therapy with a new Phase 1/2 ASPIRE-FTD cohort, reporting encouraging early data, securing strategic funding and regaining full programme rights.
AviadoBio | 01/04/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy